Compare Stocks: IMA, TARA, KROS, and CUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$28.83 -5.5%	$29.28	$4.97 ▼ $45.50	$207.35M	2.45	342,573 shs	22,941 shs
IMA ImageneBio	$5.12 +2.1%	$5.60	$3.94 ▼ $9.22	$58.80M	0.7	11,107 shs	20,938 shs
KROS Keros Therapeutics	$11.10 -1.9%	$10.84	$9.69 ▼ $22.55	$220.11M	1.01	323,857 shs	11,969 shs
TARA Protara Therapeutics	$3.79 -1.2%	$4.00	$3.02 ▼ $7.82	$223.69M	1.49	777,735 shs	41,369 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+1.67%	+13.13%	+16.86%	+12.59%	-95.60%
IMA ImageneBio	-0.79%	+1.01%	-12.41%	-12.26%	-45.48%
KROS Keros Therapeutics	+1.25%	+0.71%	+5.80%	+12.54%	-28.01%
TARA Protara Therapeutics	-1.54%	-2.79%	-6.81%	+4.93%	+23.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$28.83 -5.5%	$29.28	$4.97 ▼ $45.50	$207.35M	2.45	342,573 shs	22,941 shs
IMA ImageneBio	$5.12 +2.1%	$5.60	$3.94 ▼ $9.22	$58.80M	0.7	11,107 shs	20,938 shs
KROS Keros Therapeutics	$11.10 -1.9%	$10.84	$9.69 ▼ $22.55	$220.11M	1.01	323,857 shs	11,969 shs
TARA Protara Therapeutics	$3.79 -1.2%	$4.00	$3.02 ▼ $7.82	$223.69M	1.49	777,735 shs	41,369 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+1.67%	+13.13%	+16.86%	+12.59%	-95.60%
IMA ImageneBio	-0.79%	+1.01%	-12.41%	-12.26%	-45.48%
KROS Keros Therapeutics	+1.25%	+0.71%	+5.80%	+12.54%	-28.01%
TARA Protara Therapeutics	-1.54%	-2.79%	-6.81%	+4.93%	+23.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	1.00	Sell	N/A	N/A
IMA ImageneBio	2.20	Hold	$29.00	478.84% Upside
KROS Keros Therapeutics	2.33	Hold	$20.50	81.26% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	585.38% Upside

Current Analyst Ratings Breakdown

Latest IMA, TARA, KROS, and CUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/13/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/12/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/4/2026	KROS Keros Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $23.00
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/17/2026	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$27.47M	8.06	N/A	N/A	$10.08 per share	3.03
IMA ImageneBio	$800K	71.08	N/A	N/A	$11.91 per share	0.42
KROS Keros Therapeutics	$244.06M	0.92	$4.58 per share	2.47	$15.51 per share	0.73
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.80 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-620.06%	-291.15%	11/12/2026 (Estimated)
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	11/4/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)

Latest IMA, TARA, KROS, and CUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	N/A	1.25	1.25
IMA ImageneBio	N/A	21.47	21.47
KROS Keros Therapeutics	N/A	21.96	21.96
TARA Protara Therapeutics	N/A	10.97	10.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
IMA ImageneBio	75.00%
KROS Keros Therapeutics	71.56%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	14.56%
IMA ImageneBio	2.22%
KROS Keros Therapeutics	12.60%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	7.26 million	6.21 million	Optionable
IMA ImageneBio	70	11.35 million	11.10 million	Not Optionable
KROS Keros Therapeutics	100	19.83 million	17.33 million	Optionable
TARA Protara Therapeutics	30	59.10 million	54.60 million	Optionable

IMA, TARA, KROS, and CUE Headlines

Recent News About These Companies

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8 at 4:05 PM | globenewswire.com

Protara Therapeutics (NASDAQ:TARA) Raised to "Sell" at Wall Street Zen

September 5, 2026 | americanbankingnews.com

Protara Therapeutics (NASDAQ:TARA) Upgraded to Sell at Wall Street Zen

September 5, 2026 | marketbeat.com

Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA

August 29, 2026 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 29, 2026 | marketbeat.com

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

August 21, 2026 | tipranks.com

Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA

August 17, 2026 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Issues Negative Forecast for TARA Earnings

August 14, 2026 | marketbeat.com

Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

August 14, 2026 | marketbeat.com

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 12, 2026 | markets.businessinsider.com

Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results

August 11, 2026 | marketbeat.com

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

August 11, 2026 | seekingalpha.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMA, TARA, KROS, and CUE Company Descriptions

Cue Biopharma NASDAQ:CUE

$28.83 -1.67 (-5.48%)

As of 10:19 AM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

ImageneBio NASDAQ:IMA

$5.12 +0.11 (+2.12%)

As of 10:19 AM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Keros Therapeutics NASDAQ:KROS

$11.10 -0.21 (-1.86%)

As of 10:19 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Protara Therapeutics NASDAQ:TARA

$3.78 -0.05 (-1.17%)

As of 10:18 AM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, TARA, KROS, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, TARA, KROS, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, TARA, KROS, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, TARA, KROS, and CUE Company Descriptions

Cue Biopharma NASDAQ:CUE

ImageneBio NASDAQ:IMA

Keros Therapeutics NASDAQ:KROS

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, TARA, KROS, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, TARA, KROS, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, TARA, KROS, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, TARA, KROS, and CUE Company Descriptions

Cue Biopharma NASDAQ:CUE

ImageneBio NASDAQ:IMA

Keros Therapeutics NASDAQ:KROS

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools